Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ509509,50,30
KB803,5804,50,06
PKN81,6481,70,86
Msft-0,15
Nokia3,13753,1410,32
IBM-0,01
Daimler AG49,10549,110,73
PFE0,42
11.12.2019 9:17:00
Indexy online
AD Index online
select
AD Index online
 

  • 10.12.2019
Biogen Idec (BIIB.O, NASDAQ Cons)
Závěr k 10.12.2019 Změna (%) Změna (USD) Objem obchodů (ks)
297,20 0,56 1,65 1 227 234
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 11.12.2019
Popis společnosti
Obecné informace
Název společnostiBiogen Inc
TickerBIIB
Kmenové akcie:Ordinary Shares
RICBIIB.O
ISINUS09062X1037
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series X
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.09.2019
Počet zaměstnanců k 31.12.2018 7 800
Akcie v oběhu k 24.10.2019 184 447 218
Počet akcionářů k 31.12.2018 600
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice225 Binney St
MěstoCAMBRIDGE
PSČ02142-1031
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 814 642 000
Fax13026365454

Business Summary: Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Financial Summary: BRIEF: For the nine months ended 30 September 2019, Biogen Inc revenues increased 8% to $10.71B. Net income increased 28% to $4.45B. Revenues reflect Product, net increase of 5% to $8.46B, Revenue Sales of Goods & Services increase of 17% to $1.69B, Other Rev from Biz Related Activ. increase of 34% to $562M. Net income benefited from Other Research and development decrease of 21% to $1.52B (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations



  • Poslední aktualizace: 11.12.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardStelios Papadopoulos70
Chief Executive Officer, DirectorMichel Vounatsos5706.01.201718.04.2016
Chief Financial Officer, Executive Vice PresidentJeffrey Capello5411.12.2017
Chief Human Resource Officer, Executive Vice PresidentGinger Gregory5117.07.201717.07.2017
Executive Vice President, Chief Legal Officer and SecretarySusan Alexander6230.01.2006
Executive Vice President, Pharmaceutical Operations and TechnologyAlphonse Galdes-01.10.201901.10.2019
Executive Vice President, Head of Global Marketing, Market Access and Customer InnovationChirfi Guindo5307.11.201707.11.2017
Executive Vice President, Corporate DevelopmentDaniel Karp4111.06.201811.06.2018
Executive Vice President, Research and Development, Chief Medical OfficerAlfred Sandrock6129.09.2019
Chief Accounting Officer, Vice PresidentRobin Kramer-19.11.201819.11.2018